PMID- 16855388
OWN - NLM
STAT- MEDLINE
DCOM- 20070420
LR  - 20200930
IS  - 1538-4047 (Print)
IS  - 1538-4047 (Linking)
VI  - 5
IP  - 9
DP  - 2006 Sep
TI  - The BRK tyrosine kinase is expressed in high-grade serous carcinoma of the ovary.
PG  - 1136-41
AB  - BACKGROUND: We identified the BRK tyrosine kinase in a PCR-based screen of 
      tyrosine kinases expressed by ovarian tumors. BRK expression is restricted to 
      normal differentiating epithelial cells and its overexpression may play a role in 
      processes related to tumor development and growth. Its expression in normal ovary 
      and ovarian tumors has not previously been described, and is the focus of this 
      study. METHODS: BRK expression levels were determined in 14 normal ovaries and 
      138 high-grade, late stage serous carcinomas of the ovary by immunohistochemical 
      analysis, and in 19 ovarian cancer cell lines and immortalized ovarian surface 
      epithelium by Western blot analysis. Furthermore, BRK/PTK6 gene copy number was 
      determined in seven primary serous carcinomas by fluorescence in situ 
      hybridization. RESULTS: Immunohistochemical studies indicate that BRK is highly 
      expressed in 97/138 (70%) of high-grade, serous carcinomas of the ovary, but is 
      absent in normal ovarian surface epithelia. BRK is also expressed by 9/19 of 
      ovarian cancer cell lines, but is undetectable in immortalized ovarian surface 
      epithelium. Interestingly, the BRK gene has been mapped to chromosome 20q13.3, a 
      site frequently amplified in ovarian cancers, and associated with poor prognosis. 
      We have determined by fluorescence in situ hybridization (FISH) that BRK is 
      specifically amplified at low levels in 6/7 primary ovarian carcinomas. 
      CONCLUSIONS: The amplification of the BRK gene and overexpression of BRK protein 
      in the majority of high-grade serous carcinomas and ovarian cancer cell lines 
      suggest that BRK may play a role in the development and growth of ovarian tumors.
FAU - Schmandt, Rosemarie E
AU  - Schmandt RE
AD  - Department of Gynecologic Oncology, The University of Texas MD Anderson Cancer 
      Center, Houston, Texas 77230-1439, USA. rschmand@mdanderson.org
FAU - Bennett, Marsha
AU  - Bennett M
FAU - Clifford, Stephanie
AU  - Clifford S
FAU - Thornton, Angela
AU  - Thornton A
FAU - Jiang, Feng
AU  - Jiang F
FAU - Broaddus, Russell R
AU  - Broaddus RR
FAU - Sun, Charlotte C
AU  - Sun CC
FAU - Lu, Karen H
AU  - Lu KH
FAU - Sood, Anil K
AU  - Sood AK
FAU - Gershenson, David M
AU  - Gershenson DM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20060928
PL  - United States
TA  - Cancer Biol Ther
JT  - Cancer biology & therapy
JID - 101137842
RN  - 0 (Neoplasm Proteins)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (PTK6 protein, human)
SB  - IM
MH  - Cell Line, Tumor
MH  - Cloning, Molecular
MH  - Cystadenocarcinoma, Serous/*enzymology/pathology
MH  - Female
MH  - Gene Amplification
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Neoplasm Proteins/*biosynthesis/genetics/metabolism
MH  - Ovarian Neoplasms/*enzymology/genetics/pathology
MH  - Protein-Tyrosine Kinases/*biosynthesis/genetics/metabolism
EDAT- 2006/07/21 09:00
MHDA- 2007/04/21 09:00
CRDT- 2006/07/21 09:00
PHST- 2006/07/21 09:00 [pubmed]
PHST- 2007/04/21 09:00 [medline]
PHST- 2006/07/21 09:00 [entrez]
AID - 2953 [pii]
AID - 10.4161/cbt.5.9.2953 [doi]
PST - ppublish
SO  - Cancer Biol Ther. 2006 Sep;5(9):1136-41. doi: 10.4161/cbt.5.9.2953. Epub 2006 Sep 
      28.